Company Quick10K Filing
Angiosoma
10-Q 2020-03-31 Filed 2020-05-05
10-Q 2019-12-31 Filed 2020-02-14
10-K 2019-09-30 Filed 2019-12-31
10-Q 2019-06-30 Filed 2019-08-02
10-Q 2019-03-31 Filed 2019-05-15
10-Q 2018-12-31 Filed 2019-02-19
10-K 2018-09-30 Filed 2019-01-03
10-Q 2018-06-30 Filed 2018-08-01
10-Q 2018-03-31 Filed 2018-05-21
10-Q 2017-12-31 Filed 2018-02-15
10-K 2017-09-30 Filed 2018-01-16
10-Q 2017-06-30 Filed 2017-08-18
10-Q 2017-03-31 Filed 2017-05-19
10-Q 2016-12-31 Filed 2017-04-10
10-K 2016-09-30 Filed 2017-03-29
10-Q 2016-06-30 Filed 2016-09-13
10-Q 2016-03-31 Filed 2016-05-23
10-Q 2015-12-31 Filed 2016-02-22
10-K 2015-09-30 Filed 2016-01-13
10-Q 2015-06-30 Filed 2015-08-17
10-Q 2015-03-31 Filed 2015-05-15
10-Q 2014-12-31 Filed 2015-02-17
10-K 2014-09-30 Filed 2015-01-14
10-Q 2014-06-30 Filed 2014-08-19
10-Q 2014-03-31 Filed 2014-05-20
10-Q 2013-12-31 Filed 2014-02-14
10-K 2013-09-30 Filed 2014-01-14
10-Q 2013-06-30 Filed 2013-08-14
10-Q 2013-03-31 Filed 2013-05-15
10-Q 2012-12-31 Filed 2013-02-14
10-K 2012-09-30 Filed 2013-01-15
10-Q 2012-06-30 Filed 2012-08-14
10-Q 2012-03-31 Filed 2012-05-21
10-Q 2011-12-31 Filed 2012-02-14
10-K 2011-09-30 Filed 2011-12-29
10-Q 2011-06-30 Filed 2011-08-11
10-Q 2011-03-31 Filed 2011-05-04
10-Q 2010-12-31 Filed 2011-03-10
8-K 2019-10-28 Regulation FD
8-K 2019-10-25 Regulation FD
8-K 2019-10-16 Regulation FD, Exhibits
8-K 2019-08-16 Regulation FD, Exhibits
8-K 2018-12-13 Regulation FD, Exhibits
8-K 2018-06-14 Officers, Regulation FD, Exhibits
8-K 2018-05-14 Regulation FD, Exhibits
8-K 2018-02-23 Officers, Regulation FD
8-K 2017-09-30 Leave Agreement

Angiosoma Financials

SOAN Metrics, Comps, Filings

Quarterly | Annual

Business

AngioSoma is a wellness company marketing a line of nutraceutical supplements under our SomaCeuticalsTM identity as well as continuing to pursue the clinical stage pharmaceutical drug LiprostinTM focused on improving the effectiveness of current standard-of-care treatments, especially related to endovascular interventions in the treatment of peripheral artery disease (PAD).

We acquired all intellectual property rights to LiprostinTM, and were issued a patent for a controlled drug delivery system. It uses the generic drug, AlprostadilTM, combined with Prostaglandin E1which effectively treats Peripheral Artery Disease or PAD. There is significant opportunity with 8 million US diagnosed cases of PAD costing $212 - $389 billion annually. PAD costs exceed diabetes, coronary artery disease and cancers. It is reported that 60% to 70% of diabetics contract peripheral artery disease, often resulting in amputation as treatment. LiprostinTM has a significant history but of greatest interest was the clinical data treating diabetic ulcers. We are in discussions with several contract research organizations for completion of our FDA protocol for Phase III and submission of our new drug application for marketing in the US and its territories.


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Equity

Income Statement ($MM Quarterly)

Revenue, G Profit, Net Income

Cash Flow ($MM Quarterly)

Ops, Inv, Fin

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Natcore Technology (NXT)
OncBioMune (OBMP) 0 0.0 -1,707% 413 14,090 0 0 -7,048 -5,617 -136
Cantabio Pharmaceuticals (CTBO) 0 0.9 -474% 326 2,215 0 0 -1,543 -331 -283
Amplitude Healthcare (AMHCU)
GIFA (FRFS) 0 63% -0.9 43% 80 362 98 62 34 34 -30
Highcom Global Security (HCGS) 0 41% -0.8 1% 9,334 1,222 4,918 2,033 57 172 -131
Nutra Pharma (NPHC) 0 71% -0.2 -2,939% 252 5,614 106 75 -7,398 -6,591 1,498
Premier Biomedical (BIEI) 0 58% -0.3 -183% 186 2,304 13 8 -340 -238 75
Electromedical Technologies (ELCQ)
DigitalTown (DGTW) 0 12,618% 0.0 -16,557% 34 2,761 -2 -220 -5,706 -5,268 -34
Life Clips (LCLP) 0 135% -0.7 -21,823% 16 9,270 -86 -116 -3,494 -3,182 2,355
Anchiano Therapeutics (ANCN)
X Rail Entertainment (XREE) 0 -0.1 -1,441,401% 0 3,429 0 0 -5,261 -5,732 345
Bulova Technologies (BTGI)
Angiosoma (SOAN) 0 64% -0.2 -475% 142 828 0 0 -675 -315 66
GH Capital (GHHC) 0 66% -0.0 -2,680% 89 331 211 139 -2,374 -2,374 59
Galileo Acquisition (GLEO)
Sunshine Biopharma (SBFM) 0 30% 0.1 -864% 146 889 130 38 -1,264 -1,160 -82
True Drinks Holdings (TRUU) 0 57% 1.7 -26% 9,780 7,642 12,437 7,052 -2,515 -2,482 -4,166
Triton Emission Solutions (DSOX) 0 0.0 -10,306% 20 18,837 0 0 -2,068 -831 -1

Balance Sheet ($'000)2011-06-302011-09-302011-12-312012-03-312013-06-302014-03-312014-12-312015-12-312016-09-302016-12-312017-03-312017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash48221572049135608146567112925484105100
Accounts Receivable22166
Inventory4440404040
PP&E111111
Assets48221263570412473303171522257888131125110139159142
Accounts Payable158268
Long-Term Debt83893587187169886969194162167209166
Liabilities263279444493566603377860894995649830874901995955983887828
Stockholders' Equity23-10-78-18178-154-130-74-843-879-973-624-752-786-769-871-845-843-728-685
Income Statement ($'000)2011-06-302011-09-302011-12-312012-03-312013-06-302014-03-312014-12-312015-12-312016-09-302016-12-312017-03-312017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Revenue035119000000000
Cost of Revenue00000
Gross Profit00000
R&D
SG&A153969103125152104119372371201294270130715462
Tax000000000000000
Net Income-17-32-69-103-178-182-226-208-3,294-317-195-465-40-91-328-190-1-156
Cash Flow ($'000)2011-06-302011-09-302011-12-312012-03-312013-06-302014-03-312014-12-312015-12-312016-09-302016-12-312017-03-312017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash Operating-29-63-92-69-9060-23-15-14-34-54-73-70-53-64
Cash Investing0-206-0-060000
Cash Financing3423547190-6018226535101351007460